OBT076

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
OBT076

GtoPdb Ligand ID: 13819

Synonyms: MEN-1309 | MEN1309 | OBT-076

Compound class: Synthetic organic

Comment: OBT076 is an antibody-drug conjugate (ADC) that comprises a fully human IgG1 anti-CD205 antibody conjugated by a cleavable linker to the cytotoxic maytansinoid microtubule disruptor DM4 [2]. It was designed for anti-tumour potential in solid and liquid cancers [1,3]DM4.

References
1. Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G et al.. (2020) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica, 105 (11): 2584-2591. [PMID:33131247]
2. Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C et al.. (2019) MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther, 18 (9): 1533-1543. [PMID:31227646]
3. Terrett JA, Ackroyd JE. (2015) Conjugated antiboides against ly75 for the treatment of cancer. Patent number: WO2015052537A1. Assignee: Oxford Biotherapeutics Ltd. Priority date: 10/10/2014. Publication date: 16/04/2015.

References

1. Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G et al.. (2020)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Haematologica, 105 (11): 2584-2591. [PMID:33131247]

2. Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C et al.. (2019)
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Mol Cancer Ther, 18 (9): 1533-1543. [PMID:31227646]

3. Terrett JA, Ackroyd JE. (2015)
Conjugated antiboides against ly75 for the treatment of cancer.
Patent number: WO2015052537A1. Assignee: Oxford Biotherapeutics Ltd. Priority date: 10/10/2014. Publication date: 16/04/2015.